Safety of Enalapril in Infants Admitted to the Neonatal Intensive Care Unit
Authors:
- on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering CommitteeOCon behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee
- Reese H. ClarkRCReese H. Clark
- P. Brian SmithPSP. Brian Smith
- 8 November 2016
- journal article
- research article
- Published by Springer Nature in Pediatric Cardiology
- Vol. 38 (1) , 155-161
Abstract
Enalapril is used to treat hypertension and congestive heart failure in infants. However, enalapril is not labeled for neonates, and safety data in infants are sparse. To evaluate the safety of enalapril in young infants, we conducted a retrospective cohort study of infants who were exposed to enalapril in the first 120 days of life and were cared for in 348 neonatal intensive care units from 1997 to 2012. We determined the proportion of exposed infants who developed adverse events, including death, hypotension requiring pressors, hyperkalemia, and elevated serum creatinine. Using multivariable logistic regression, we examined risk factors for adverse events, including postnatal age at first exposure, exposure duration, gestational age group, small for gestational age status, race, sex, 5-min Apgar score, and inborn status. Of a cohort of 887,910 infants, 662 infants (0.07%) were exposed to enalapril. Among exposed infants, 142 infants (21%) suffered an adverse event. The most common adverse event was hyperkalemia (13%), followed by elevated serum creatinine (5%), hypotension (4%), and death (0.5%). Significant risk factors for adverse events included postnatal age <30 days at first exposure and longer exposure duration. This study is the largest to date examining the safety of enalapril in young term and preterm infants without significant structural cardiac disease.Keywords
Funding Information
- National Institute of Child Health and Human Development (5T32GM086330-03, HHSN275201000003I, 1R01-HD081044-01)
- National Institutes of Health (KL2TR001115-03)
- National Center for Advancing Translational Sciences (UL1TR001117, UL1TR001117)
- U.S. Food and Drug Administration (1R18-FD005292-01)
- U.S. Department of Health and Human Services (HHS0100201300009C)
This publication has 41 references indexed in Scilit:
- Incidence and treatment of hypertension in the neonatal intensive care unitJournal of the American Society of Hypertension, 2011
- Hyperkalemia Associated with Use of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor BlockersCardiovascular Therapeutics, 2011
- Enalapril in Infants With Single VentricleCirculation, 2010
- Early dialysis in a neonate with intrauterine lisinopril exposureArchives of Disease in Childhood - Fetal and Neonatal Edition, 2003
- A Double‐Blind, Placebo‐Controlled, Dose‐Response Study of the Effectiveness and Safety of Enalapril for Children with HypertensionThe Journal of Clinical Pharmacology, 2002
- Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD)American Heart Journal, 1996
- Use of enalapril in neonatal hypertensionActa Paediatrica, 1995
- Treatment of Neonatal Renovascular Hypertension with Intravenous EnalaprilAmerican Journal of Perinatology, 1992
- Cough and converting enzyme inhibitorsEuropean Journal of Pediatrics, 1992
- Treatment of neonatal hypertension with enalaprilatThe Journal of Pediatrics, 1990